Clinical value of 131I and operation in the treatment of papillary thyroid carcinoma
10.3969/j.issn.1005-1678.2017.05.026
- VernacularTitle:手术联合131I、甲状腺片治疗甲状腺乳头状癌疗效观察
- Author:
Huafeng LANG
;
Fang ZHAO
;
Jing WANG
;
Pei CHEN
- Keywords:
papillary thyroid carcinoma;
131I;
isotope
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):82-84
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of surgical treatment combined with 131I in the treatment of thyroid papillary carcinoma.Methods45 cases of papillary thyroid cancer patients were selected from January 2008 to January 2012 in our hospital.All of the patients were treated with total thyroidectomy surgical,postoperative underwent thyroid hormone and 131I radionuclide therapy,The patients were followed up.ResultsAt 3 months or 6 months after operation,the levels of serum P53,Fas and TNF-a were significantly higher than immediate time after surgery (P<0.05) and cyclin E protein levels were significantly lower than immediate time after surgery (P<0.05).There were no difference of serum P53,Fas,TNF-and Cyclin E protein levels between at 3 months and 6 months after operation.During five years of follow-up, the 5-year recurrence rate of 4.4%,and the distant metastasis rate was 2.2%.ConclusionOperation combined with 131I radionuclide therapy has good clinical results,could be used as the first choice for clinical treatment.